Polianta Ltd bought a new stake in Amedisys Inc (NASDAQ:AMED) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 14,400 shares of the health services provider’s stock, valued at approximately $1,774,000. Amedisys comprises 0.7% of Polianta Ltd’s investment portfolio, making the stock its 26th biggest position.
Several other hedge funds also recently made changes to their positions in AMED. Navellier & Associates Inc lifted its holdings in shares of Amedisys by 148.7% in the 4th quarter. Navellier & Associates Inc now owns 17,558 shares of the health services provider’s stock valued at $2,056,000 after buying an additional 10,499 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Amedisys by 67.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 28,567 shares of the health services provider’s stock valued at $3,570,000 after buying an additional 11,486 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Amedisys in the 3rd quarter valued at approximately $2,174,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Amedisys by 15.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,900 shares of the health services provider’s stock valued at $223,000 after buying an additional 251 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Amedisys in the 3rd quarter valued at approximately $3,411,000. Institutional investors own 91.91% of the company’s stock.
AMED has been the subject of several research reports. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $151.00 price objective for the company in a report on Thursday, February 7th. SunTrust Banks lifted their price objective on Amedisys to $145.00 and gave the stock a “buy” rating in a report on Friday, March 1st. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. ValuEngine cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 27th. Finally, Barclays lifted their price objective on Amedisys from $115.00 to $120.00 and gave the stock an “equal weight” rating in a report on Thursday, March 21st. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $124.72.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 27th. The health services provider reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.06. The company had revenue of $434.38 million during the quarter, compared to the consensus estimate of $427.75 million. Amedisys had a return on equity of 25.89% and a net margin of 7.18%. Amedisys’s revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.56 earnings per share. On average, research analysts anticipate that Amedisys Inc will post 4.05 EPS for the current year.
In other Amedisys news, COO Christopher Gerard sold 2,500 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $118.96, for a total transaction of $297,400.00. Following the completion of the transaction, the chief operating officer now owns 25,731 shares of the company’s stock, valued at $3,060,959.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David B. Pearce sold 4,370 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $120.01, for a total value of $524,443.70. Following the transaction, the insider now directly owns 13,129 shares of the company’s stock, valued at approximately $1,575,611.29. The disclosure for this sale can be found here. Insiders have sold 8,281 shares of company stock valued at $993,393 in the last three months. 2.60% of the stock is currently owned by company insiders.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Article: Stop Order Uses For Individual Investors
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.